Eng Marvin H, Kherallah Riyad Yazan, Guerrero Mayra, Greenbaum Adam B, Frisoli Tiberio, Villablanca Pedro, Wang Dee Dee, Lee James, Wyman Janet, O'Neill William W
Department of Medicine, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, Michigan.
Department of Medicine, Baylor College of Medicine, Houston, Texas.
Catheter Cardiovasc Interv. 2020 Aug;96(2):481-487. doi: 10.1002/ccd.28731. Epub 2020 Jan 20.
To examine the safety of utilizing transapical access during structural interventions.
Complex interventions of the mitral or aortic region sometimes require coaxial forces to orient and deliver devices. Apical access can provide coaxial countertraction for either transseptal or retrograde aortic access. This manuscript describes the single center experience of small bore transapical access.
Retrospective review of cases from 2013 to 2018 at Henry Ford Hospital was performed. Patient demographics and procedure characteristics were abstracted to describe the safety of transapical access using small bore sheaths.
A total 21 cases were performed at Henry Ford, most of them for transcatheter mitral valve replacement (81%). The mean sheath size used was 4.7 ± 0.9 Fr and protamine was used at the end of 57% of cases. All patients received nitinol-based plugs, 80.1% were from the Amplatz Duct Occluder II type. Four major complications related apical puncture occurred, two pericardial effusions, two hemothorax. Over a median follow time of 430 days (IQR 50-652) a total of five deaths occurred, two related to the procedure and three late deaths with a median time of 362 days (range 205-628 days). No deaths were associated with transapical access. Echocardiographic follow up did not detect any late structural complications from occluder devices.
Transapical access and closure with nitinol-based devices is feasible and facilitates complex interventions where coaxial forces are need for device delivery and alignment. The most common complication is bleeding and this should be kept in perspective when treating high-risk patients.
研究在结构性介入治疗中使用经心尖入路的安全性。
二尖瓣或主动脉区域的复杂介入治疗有时需要同轴力来定位和输送器械。心尖入路可为经房间隔或逆行主动脉入路提供同轴反向牵引力。本文描述了小口径经心尖入路的单中心经验。
对亨利福特医院2013年至2018年的病例进行回顾性研究。提取患者人口统计学和手术特征,以描述使用小口径鞘管的经心尖入路的安全性。
亨利福特医院共进行了21例手术,其中大多数为经导管二尖瓣置换术(81%)。使用的鞘管平均尺寸为4.7±0.9 Fr,57%的病例在手术结束时使用了鱼精蛋白。所有患者均接受了镍钛合金封堵器,80.1%来自Amplatz Duct Occluder II型。发生了4例与心尖穿刺相关的主要并发症,2例心包积液,2例血胸。在中位随访时间430天(四分位间距50 - 652天)内,共发生5例死亡,2例与手术相关,3例为晚期死亡,中位时间为362天(范围205 - 628天)。没有死亡与经心尖入路相关。超声心动图随访未发现封堵器装置的任何晚期结构并发症。
经心尖入路并用镍钛合金装置进行封堵是可行的,有助于在需要同轴力来输送和对准装置的复杂介入治疗中进行操作。最常见的并发症是出血,在治疗高危患者时应考虑到这一点。